Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.

Consistent with earlier reports from the study, the 7-year invasive disease-free survival (iDFS ... The primary endpoint was iDFS at 3 years, and OS was a key secondary endpoint.

Compass Therapeutics has announced top-line data from its ongoing COMPANION-002 trial investigating its antibody-based therapeutic for biliary tract cancer (BTC), tovecimig.

Dose escalation offers no survival benefits but increases grade ≥ 3 toxicity compared with standard radiation in patients ...

In a statistical analysis, Brukinsa resulted in fewer cases of disease progression or death and resulted in lower overall healthcare costs than Imbruvica in patients with chronic lymphocytic leukemia.

Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate CORT stock a Strong Buy.

The primary endpoint was event-free survival, defined as freedom from ... The study was supported by the Noncommunicable Chronic Diseases-National Science and Technology Major Project, National ...

met its primary endpoint of improved progression-free survival, as assessed by blinded independent central review (PFS-BICR). In ROSELLA, patients treated with relacorilant in addition to nab ...

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

Equillium’s phase 3 graft-versus-host disease (GVHD) trial has missed ... itolizumab versus 72 days for placebo—and failure-free survival. Post hoc analyses—durable CR evaluating Day 29 ...

RFS served as the primary endpoint. OS, adverse events and ... radical hysterectomy had an associated lower rate of disease-free survival compared with open radical hysterectomy for women with ...

Corcept Therapeutics shares nearly doubled in premarket trading Monday after the company said it received positive data from its phase 3 ovarian cancer treatment trial. Shares rose 93% ahead of the ...